Still sees 2025 non-GAAP gross margin on net product sales 86%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron: Buy Rating Supported by Eylea Stability and Pipeline Potential
- Regeneron Initiates Promising Study on REGN7041 for Eye Inflammation
- Regeneron’s New Parkinson’s Study: A Potential Game-Changer?
- Regeneron’s New Phase 3 Study: A Potential Game Changer in VTE Prevention?
- Regeneron Pharmaceuticals Advances with ALN-CFB Study for PNH Treatment